Bulk Pharmaceutical API Sources for MOEXIPRIL HYDROCHLORIDE

Bulk Pharmaceutical API Sources for MOEXIPRIL HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		54889
MolPort		MolPort-003-666-743
ABI Chem		AC1L1HXF
ChemMol		49422713

MOEXIPRIL HYDROCHLORIDE: BULK ACTIVE PHARMACEUTICAL INGREDIENT SOURCING

Last updated: February 19, 2026

This report analyzes the landscape of bulk Active Pharmaceutical Ingredient (API) sources for Moexipril Hydrochloride, a widely used angiotensin-converting enzyme (ACE) inhibitor. The analysis focuses on key manufacturers, production capacities, quality certifications, and supply chain considerations relevant to pharmaceutical companies and investors.

What is Moexipril Hydrochloride?

Moexipril Hydrochloride is an oral prodrug that, upon absorption, is hydrolyzed to its active metabolite, moexiprilat. Moexiprilat inhibits the angiotensin-converting enzyme (ACE), which plays a crucial role in the renin-angiotensin-aldosterone system (RAAS). By blocking ACE, moexiprilat reduces the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation, decreased aldosterone secretion, and ultimately, a reduction in blood pressure. It is indicated for the treatment of hypertension [1].

The chemical structure of Moexipril Hydrochloride is (3S)-2-[(2S)-2-[[(1S)-1-Carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 1-ethyl ester hydrochloride. Its molecular formula is C24H34N2O5 · HCl, and its molecular weight is approximately 466.99 g/mol [2].

Leading API Manufacturers for Moexipril Hydrochloride

The global supply of Moexipril Hydrochloride API is concentrated among a select group of manufacturers. These companies often possess significant expertise in complex organic synthesis and adherence to stringent pharmaceutical manufacturing standards. Key players include:

• Daiichi Sankyo Company, Limited: As the originator of moexipril, Daiichi Sankyo (Japan) maintains significant manufacturing capabilities. Their production is characterized by a focus on proprietary synthesis routes and rigorous quality control.
• Torrent Pharmaceuticals Ltd.: A major Indian pharmaceutical company, Torrent Pharma has established itself as a significant supplier of various APIs, including Moexipril Hydrochloride. They leverage large-scale manufacturing facilities and a strong presence in both regulated and emerging markets.
• Divi's Laboratories Limited: Another prominent Indian API manufacturer, Divi's Labs is known for its cost-effective production and high-volume output. Their capabilities include complex chemical synthesis and a robust supply chain.
• Teva Pharmaceutical Industries Ltd.: While primarily a finished dosage form manufacturer, Teva also produces a range of APIs or sources them through its extensive global network. Their involvement signifies a broad market reach and established quality systems.
• Other Manufacturers: Several other companies, particularly in India and China, also produce Moexipril Hydrochloride API. These include companies like Dr. Reddy's Laboratories, Cipla Limited, and Zhejiang NHU Company Ltd., though their market share and specific production capacities may vary.

Production Capacity and Scale

Estimates of specific production capacities for Moexipril Hydrochloride API are proprietary and not publicly disclosed by most manufacturers. However, leading suppliers are understood to operate multi-tonnage production lines to meet global demand. Factors influencing production scale include:

• Market Demand: The global prevalence of hypertension and the established therapeutic use of moexipril drive demand.
• Manufacturing Technology: Efficiency of synthesis routes, process optimization, and automation contribute to higher output.
• Regulatory Compliance: Investment in Good Manufacturing Practice (GMP) compliant facilities and processes can enable larger-scale, continuous production.

For example, a facility capable of producing several metric tons of API per batch would be considered substantial. Manufacturers typically aim for economies of scale to reduce per-unit production costs, a critical factor in the competitive generic API market.

Quality and Regulatory Compliance

The production of Moexipril Hydrochloride API must adhere to strict global regulatory standards to ensure patient safety and drug efficacy. Key certifications and compliance aspects include:

• Good Manufacturing Practices (GMP): Compliance with GMP guidelines, as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others, is mandatory. This covers all aspects of production, including facility design, personnel training, raw material control, process validation, and quality control testing.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies (e.g., FDA's Type II DMF). A DMF provides detailed information about the manufacturing process, facilities, quality controls, and stability of the API. This allows drug product manufacturers to reference the DMF in their marketing applications without disclosing proprietary manufacturing details.
• Certificates of Suitability (CEPs): For the European market, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) demonstrates that the API complies with the monographs of the European Pharmacopoeia.
• Inspections: Manufacturing sites are subject to regular inspections by regulatory authorities to verify ongoing compliance with GMP. Successful FDA and EMA inspections are critical for market access in these regions.
• Impurity Profiling: Comprehensive control and characterization of impurities, including potential genotoxic impurities, are essential. Regulatory guidelines like ICH Q3A (Impurities in New Drug Substances) and ICH M7 (Assessment and Control of DNA Reactive (Mutagenic) Impurities) are critical.

Key Quality Parameters

• Assay: The purity of Moexipril Hydrochloride API is typically specified as not less than 98.0% and not more than 102.0% on the anhydrous, solvent-free basis, depending on pharmacopeial requirements [3].
• Related Substances/Impurities: Limits are set for known and unknown impurities, often measured by High-Performance Liquid Chromatography (HPLC). These limits are typically in the range of 0.1% to 0.5% for individual impurities and a total impurity limit.
• Water Content: Specified limits, often determined by Karl Fischer titration, to ensure API stability.
• Residual Solvents: Compliance with ICH Q3C guidelines for residual solvents used during synthesis.

Table 1 summarizes typical quality attributes and regulatory considerations.

Attribute	Typical Specification	Regulatory Relevance
Assay (Purity)	≥ 98.0% and ≤ 102.0% (anhydrous, solvent-free)	Pharmacopeial compliance (USP, EP, JP), FDA, EMA
Related Substances/Impurities	Individual impurities ≤ 0.1-0.5%; Total impurities ≤ 1.0% (specific limits vary)	ICH Q3A, ICH Q3D, Pharmacopeias, DMF filing
Water Content	e.g., ≤ 1.0%	Stability, Pharmacopeial compliance
Residual Solvents	Compliant with ICH Q3C guidelines (Class 1, 2, 3 solvents)	ICH Q3C, DMF filing
Particle Size Distribution	May be specified for finished dosage form performance	Formulation development, Bioequivalence
Polymorphism	Defined crystalline form to ensure consistent dissolution and bioavailability	Process development, Patent considerations
Microbial Limits	Meets pharmacopeial requirements for non-sterile APIs	USP <61>, <62>; EP 2.6.12, 2.6.13
GMP Compliance	Facility inspections, Process validation, Quality Management System	FDA, EMA, PMDA, WHO GMP certification; Market access
Drug Master File (DMF)	Filed with regulatory agencies (FDA, EMA, etc.)	Enables drug product approval (ANDA, NDA, MAA)
Certificate of Suitability (CEP)	Issued by EDQM for European market access	European market compliance

Supply Chain Dynamics and Considerations

The sourcing of Moexipril Hydrochloride API involves several strategic considerations for pharmaceutical companies:

• Geopolitical Risks: Over-reliance on a single geographic region for API manufacturing can expose companies to supply chain disruptions due to political instability, trade disputes, or natural disasters. Diversification of suppliers across different regions, such as India, China, and established Western markets, is advisable.
• Lead Times and Inventory Management: API production is a multi-step process. Understanding the lead times from order placement to delivery is crucial for effective inventory management and to avoid stock-outs. Manufacturers often require significant advance notice for large-volume orders.
• Intellectual Property: While the primary patents for moexipril may have expired, process patents related to novel synthesis routes or polymorphic forms could still exist, impacting freedom to operate for certain manufacturing processes. Thorough IP due diligence is necessary.
• Cost of Goods Sold (COGS): API cost is a significant component of the overall COGS for finished drug products. Manufacturers continuously strive for process optimization and yield improvement to remain competitive. Fluctuations in raw material costs and energy prices can impact API pricing.
• Auditing and Qualification: Rigorous auditing of potential API suppliers is essential to ensure they meet quality, regulatory, and ethical standards. This involves site audits, review of quality systems, and verification of regulatory filings.
• Dual Sourcing Strategy: To mitigate supply chain risks, many pharmaceutical companies adopt a dual-sourcing strategy, qualifying at least two independent suppliers for critical APIs like Moexipril Hydrochloride.

Raw Material Sourcing

The synthesis of Moexipril Hydrochloride involves various chemical intermediates. The availability and quality of these starting materials and intermediates are critical. Key raw materials include:

• L-Proline derivatives
• Phenylalanine derivatives
• Isoquinoline derivatives
• Ethyl acetoacetate derivatives
• Various chiral catalysts and reagents

The sourcing of these raw materials often originates from specialized chemical manufacturers, further complicating the supply chain. Disruptions in the supply of any of these key precursors can impact the final API production.

Future Trends and Market Outlook

The market for Moexipril Hydrochloride API is expected to remain stable, driven by its established efficacy and inclusion in therapeutic guidelines for hypertension management.

• Generic Competition: The generic nature of moexipril means that pricing remains a key competitive factor. Manufacturers with efficient production processes and strong supply chain management are best positioned.
• Regulatory Scrutiny: Ongoing and increasing regulatory scrutiny on API quality, impurity control, and data integrity will continue to shape the supplier landscape. Companies with robust quality systems and a proactive approach to regulatory compliance will thrive.
• Consolidation: The API manufacturing sector may see further consolidation as larger players acquire smaller ones to gain market share, expand capacity, or acquire specific technological capabilities.
• Emerging Markets: Growth in healthcare expenditure and increasing access to essential medicines in emerging markets will continue to drive demand for established APIs like Moexipril Hydrochloride.

Key Takeaways

• Moexipril Hydrochloride API manufacturing is dominated by a few key global players, primarily in India and Japan, with significant capacity for multi-tonnage production.
• Strict adherence to GMP and successful regulatory filings (DMFs, CEPs) are non-negotiable for market access in regulated regions like the US and EU.
• Quality parameters, including assay, impurity profile, and residual solvents, are critical and subject to pharmacopeial standards and regulatory oversight.
• Supply chain resilience requires diversification of suppliers, proactive risk assessment for geopolitical and raw material issues, and robust supplier qualification processes.
• The market is characterized by generic competition, emphasizing cost-efficiency and continuous process improvement, alongside increasingly stringent regulatory expectations.

Frequently Asked Questions

1. What are the primary regulatory bodies whose GMP standards must be met for Moexipril Hydrochloride API intended for the US market? The primary regulatory body is the U.S. Food and Drug Administration (FDA). Manufacturers must comply with FDA's Current Good Manufacturing Practice (cGMP) regulations, outlined in 21 CFR Parts 210 and 211, and ensure their Drug Master File (DMF) is accepted.

2. How does the impurity profile of Moexipril Hydrochloride API impact its marketability? A well-controlled impurity profile is critical. Manufacturers must identify, quantify, and control all impurities within pharmacopeial limits and ICH guidelines (e.g., ICH Q3A for impurities in new drug substances, ICH M7 for mutagenic impurities). Deviations can lead to regulatory non-compliance, delays in drug product approval, or product recalls.

3. Are there any significant patent restrictions that could hinder the production of generic Moexipril Hydrochloride API? The primary composition of matter patents for moexipril have likely expired. However, process patents related to novel synthesis methods, crystalline forms (polymorphs), or specific purification techniques could still be in force and require careful IP due diligence to ensure freedom to operate.

4. What is the typical lead time for ordering a substantial quantity (e.g., 1 metric ton) of Moexipril Hydrochloride API from a qualified manufacturer? Lead times can vary but generally range from 3 to 6 months for substantial quantities, accounting for raw material procurement, batch scheduling, manufacturing, quality control testing, and release. Advance planning and strong communication with the supplier are essential.

5. Which pharmacopeias typically provide the official monographs for Moexipril Hydrochloride API? Key pharmacopeias that provide monographs for Moexipril Hydrochloride API include the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), and the Japanese Pharmacopoeia (JP). Compliance with relevant pharmacopeial standards is a prerequisite for market approval.

Citations

[1] American Society of Health-System Pharmacists. (n.d.). Moexipril Hydrochloride. Professional Drug Information. Retrieved from https://www.drugs.com/monograph/moexipril-hydrochloride.html

[2] PubChem. (n.d.). Moexipril hydrochloride. National Center for Biotechnology Information. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Moexipril-hydrochloride

[3] United States Pharmacopeial Convention. (2024). United States Pharmacopeia and The National Formulary (USP-NF). (Specific monograph details for Moexipril Hydrochloride would be found within this publication).